Why Gene Editing Stocks Matter Now
The gene editing sector reached an inflection point in late 2023 when the FDA and EMA approved Casgevy, the world's first CRISPR-based therapy. That approval transformed gene editing from a laboratory curiosity into a commercial reality — and fundamentally changed the investment thesis for the entire sector. In 2026, the landscape has evolved further, with expanding clinical pipelines, new therapeutic modalities, and growing commercial infrastructure. Here are six companies that investors should be watching closely.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always consult a qualified financial advisor before making investment decisions.
CRISPR Therapeutics (CRSP)
Why it matters: CRISPR Therapeutics holds the distinction of co-developing the first approved CRISPR therapy. Casgevy (exagamglocel autotemcel), developed in partnership with Vertex Pharmaceuticals, treats sickle cell disease and transfusion-dependent beta-thalassemia by editing patients' own hematopoietic stem cells to produce fetal hemoglobin.
What to watch: The commercial rollout of Casgevy is the near-term story. Treatment requires myeloablative conditioning and specialized manufacturing — logistics that limit the pace of patient treatment. Investors are tracking the number of authorized treatment centers, patient starts per quarter, and revenue ramp. Beyond Casgevy, CRISPR Therapeutics has an in vivo gene editing program (CTX310 and CTX320) targeting cardiovascular disease by editing ANGPTL3 and PCSK9 in the liver, as well as next-generation CAR-T cell therapies using CRISPR-edited allogeneic (off-the-shelf) T cells.
Key risk: Casgevy's complex manufacturing and delivery model may limit its commercial ceiling, and competition from Lyfgenia (bluebird bio) and emerging gene therapies adds pressure.
Intellia Therapeutics (NTLA)
Why it matters: Intellia is the leader in in vivo CRISPR gene editing — administering gene editing therapy directly inside the body via lipid nanoparticle (LNP) delivery, rather than extracting, editing, and reinfusing cells. This approach could fundamentally change the economics and accessibility of gene therapy.
What to watch: Intellia's lead program, NTLA-2001 (nexiguran ziclumeran), targets transthyretin amyloidosis (ATTR) by knocking out the TTR gene in the liver with a single IV infusion. Clinical data have shown deep and durable TTR protein reductions. The program is in pivotal trials and could be the first in vivo CRISPR therapy to reach the market. Intellia's pipeline also includes programs in hereditary angioedema (NTLA-2002) and acute myeloid leukemia.
Key risk: In vivo editing is newer and less clinically validated than ex vivo approaches. Any safety signal in pivotal trials would be consequential for the entire in vivo editing field.
Beam Therapeutics (BEAM)
Why it matters: Beam is built on base editing technology licensed from David Liu's laboratory at the Broad Institute. Base editing makes precise single-letter DNA changes without double-strand breaks, potentially offering a safer and more predictable editing profile than standard CRISPR.
What to watch: Beam's lead clinical program, BEAM-101, targets sickle cell disease using base editing to activate fetal hemoglobin — a similar therapeutic strategy to Casgevy but using a fundamentally different editing mechanism. The company is also advancing programs in alpha-1 antitrypsin deficiency and is building a pipeline around its proprietary base editing and prime editing platforms. Beam's multiplex editing capabilities are particularly relevant for next-generation CAR-T therapies, where multiple simultaneous edits can improve T-cell persistence and reduce graft-versus-host risk.
Key risk: Base editing is still generating early clinical data. Beam needs to demonstrate that its platform offers meaningful clinical differentiation to justify its valuation against established CRISPR approaches.
Editas Medicine (EDIT)
Why it matters: Editas was one of the first gene editing companies, founded in 2013 with technology from Feng Zhang's laboratory at the Broad Institute. The company has undergone significant strategic shifts in recent years, refocusing its pipeline after mixed clinical results.
What to watch: Editas has pivoted toward next-generation editing approaches and in vivo programs. The company's reni-cel program for sickle cell disease continues in clinical development. Editas also holds foundational CRISPR-Cas9 intellectual property through its Broad Institute license, which gives it a role in the complex web of CRISPR patent rights. Any resolution of longstanding patent disputes could materially affect valuation.
Key risk: Editas has faced leadership turnover and pipeline restructuring. Execution risk is elevated compared to peers with more advanced clinical programs.
Verve Therapeutics (VERV)
Why it matters: Verve is focused exclusively on cardiovascular disease, using base editing to make single-dose genetic treatments for conditions driven by well-characterized genes. The company's approach targets the liver to permanently reduce levels of disease-causing proteins.
What to watch: Verve's lead program, VERVE-101, uses base editing to inactivate the PCSK9 gene, aiming to permanently lower LDL cholesterol with a single infusion. The company is also developing VERVE-102 with a next-generation LNP delivery system and VERVE-201 targeting ANGPTL3. Cardiovascular disease is the leading cause of death worldwide, and if Verve can demonstrate safe and durable cholesterol reduction in clinical trials, the addressable market is enormous.
Key risk: Verve paused its VERVE-101 program in 2024 after a patient death in the clinical trial, though the company attributed the event to preexisting cardiovascular disease. The transition to VERVE-102 with an improved delivery system will be closely scrutinized.
Caribou Biosciences (CRBU)
Why it matters: Caribou, co-founded by CRISPR pioneer Jennifer Doudna, is focused on allogeneic (off-the-shelf) cell therapies using its proprietary chRDNA (CRISPR hybrid RNA-DNA) technology. Unlike autologous therapies that require manufacturing from each patient's cells, allogeneic therapies are manufactured in advance, potentially reducing cost and treatment timelines.
What to watch: Caribou's lead program, CB-010, is an anti-CD19 allogeneic CAR-T therapy for B-cell non-Hodgkin lymphoma. The company's chRDNA technology enables highly specific gene editing with reduced off-target effects, which is critical for making multiplex-edited allogeneic T cells safe and effective. Caribou is also developing CB-011 for multiple myeloma with an immune-evasion engineering approach.
Key risk: The allogeneic cell therapy space is crowded and has historically struggled to match the efficacy and durability of autologous CAR-T therapies. Caribou needs to demonstrate that its persistence-enhancing edits translate into competitive clinical outcomes.
The Bigger Picture
Gene editing stocks are not for the faint-hearted. The sector is characterized by high binary risk — clinical trial readouts can move stock prices by 30% or more in a single day. But the underlying science is maturing rapidly, the first commercial revenues are flowing, and the clinical pipeline is broader and deeper than ever. For investors with the risk tolerance and time horizon to match, 2026 is shaping up to be a defining year for the gene editing industry.